Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
An expert discusses how education about the clinical impact of genomic testing, understanding of targeted therapies, turnaround times, and team-based approaches are essential to bridge the gap in routine comprehensive genomic profiling adoption.
EP: 1.Comprehensive Genomic Profiling Is a Cornerstone of Cancer Care
EP: 2.Putting Comprehensive Genomic Profiling into Practice With Advanced Lung Cancer
EP: 3.Clinical Impact and Perspectives on Comprehensive Genomic Profiling in Advanced Lung Cancer Management
EP: 4.Key Insights for Improving Adoption of Dual and Concurrent Testing for Cancer Care
EP: 5.What’s Next for Comprehensive Genomic Profiling in Cancer Care
EP: 6.Employing Comprehensive Genomic Testing in the NSCLC Paradigm
Video content above is prompted by the following:
Despite increasing adoption, significant gaps remain in routine comprehensive genomic profiling implementation. Education represents a core element in bridging these gaps, particularly regarding the clinical impact and value of identifying driver events for treatment selection. Clinicians need better understanding of both the testing technologies and the downstream therapeutic options available for patients with specific molecular profiles, creating a comprehensive educational approach that links diagnostic capabilities with treatment opportunities.
Enhanced education about turnaround times and behind-the-scenes testing activities helps clinicians better communicate with patients about result timelines and manage expectations effectively. Understanding the complexity of genomic testing processes enables better patient communication and workflow planning. This knowledge also helps clinical teams optimize their processes to minimize delays and ensure efficient test completion.
Successful implementation requires a multidisciplinary team approach where all health care team members understand the importance of genomic test results. Streamlined workflows and optimized processes are essential for decreasing time to results and ensuring test findings are easily visible and accessible to the entire care team. Strategies focus on providing targeted education within teams about genomic testing value and developing efficient workflows for rapid, comprehensive testing completion.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Individualizing Extended Adjuvant Therapy in HR+ Breast Cancer
June 15th 2021This article reviews individualizing extended adjuvant therapy for patients with HR+ breast cancer and includes insights from Vijayakrishna (V. K.) Gadi, MD, PhD, of the University of Illinois in Chicago, and Reshma L. Mahtani, DO, of the University of Miami Health System in Deerfield Beach, FL.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
